Metabolon, Inc.

Metabolon, Inc. is recognized as a global leader in metabolomics, a field dedicated to the systematic measurement and biological interpretation of small molecules (metabolites) within biological samples. The company's mission is to deliver biochemical data and insights that advance and accelerate the impact of life sciences research across various applications. Headquartered in Morrisville, North Carolina, Metabolon operates from its corporate offices at 617 Davis Drive, Suite 100.

Metabolon offers a comprehensive suite of metabolomics services, including untargeted metabolomics through its Global Discovery Panel, targeted metabolomics with over 150 validated methods for more than 1,000 metabolites and lipids, lipidomics, and integrated bioinformatics solutions. Their proprietary technology combines ultra-high-performance liquid chromatography/tandem accurate mass spectrometry (UHPLC/MS/MS) with the world's largest biochemical reference library, encompassing over 5,400 metabolites across more than 70 metabolic pathways. These services cater to diverse market segments, including biopharma, public health, consumer wellness, agriculture, academic research, disease research, and drug development.

Under the leadership of President and CEO Rohan F. Hastie, Ph.D., Metabolon maintains its position as a leading metabolomics service provider, celebrating 25 years of innovation in 2025. The company recently secured a new $60 million credit facility in May 2024, led by Trinity Capital, Inc., to support growth initiatives and research and development, following a $25 million equity financing in January 2023. Recent collaborations include partnerships with the Cleveland Clinic for drug development research and The Michael J. Fox Foundation for Parkinson's Research. Metabolon has also introduced multiomic integration capabilities and was certified as a Great Place To Work® for 2023-2024.